A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

New England Journal of Medicine

Volumn 316, Issue 15, 1987, Pages 889-897

  Rosenberg, Steven A ^a   Lotze, Michael T ^a   Muul, Linda M ^a   Chang, Alfred E ^a   Avis, Fred P ^a   Leitman, Susan ^a   Linehan, W Marston ^a   Robertson, Cary N ^a   Lee, Roberta E ^a   Rubin, Joshua T ^a   Seipp, Claudia A ^a   Simpson, Colleen G ^a   White, Donald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADVANCED CANCER; ADVERSE DRUG REACTION; ANEMIA; BILIRUBIN BLOOD LEVEL; BLOOD AND HEMOPOIETIC SYSTEM; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CHILL; CREATININE BLOOD LEVEL; CYTOTOXIC LYMPHOCYTE; DIGESTIVE SYSTEM; DRUG DOSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG THERAPY; EDEMA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPOTENSION; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTOTOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NERVOUS SYSTEM; NEUROTOXICITY; OLIGURIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY SYSTEM; SIDE EFFECT; THERAPY; THROMBOCYTOPENIA; WEIGHT GAIN;

EID: 0023115642     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198704093161501     Document Type: Article

References (26)

1. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.
2. Rosenberg SA. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 1984; 68: 233–55.
3. Rosenberg Lymphokine activated killer cells: a new approach to the immunotherapy of cancer. JNCI 1985; 75: 595–603.
4. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159: 495–507.
5. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9.
6. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169–88.
7. Mulé JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985; 135: 646–52.
8. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985; 45: 3735–41.
9. Lafreniere Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985; 135: 4273–80.
10. Mazumder A, Eberlein TJ, Grimm EA, et al. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 1984; 53: 896–905.
11. Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod 1984; 3: 501–11.
12. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human interleukin 2.1. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985; 134: 157–66.
13. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135: 2865–75.
14. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980; 125: 238–45.
15. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications of the adoptive immunotherapy of tumors. J Immunol 1980; 125: 1487–93.
16. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41: 4420–5.
17. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41.
18. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 1984; 44: 1946–53.
19. Rosenberg SA. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: De Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology: Philadelphia: JB Lippincott, 1986:55–91.
20. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 1986; 256: 3117–24.
21. Muul LM, Director EP, Hyatt CL, Rosenberg SA. Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 1986; 88: 265–75.
22. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412–5.
23. Siegel JP, Lane HC, Stocks NI, Quinnan GV Jr, Fauci AS. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. J Biol Response Mod 1985; 4: 596–601.
24. Atkins MB, Gould JA, Allegretta M, et al. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986; 4: 1380–91.
25. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735–42.
26. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–21.